A brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU)

Author:

Kolbin A. S.1ORCID,Belousov D. Yu.2ORCID

Affiliation:

1. FSBEI HE I. P. Pavlov SPbSMU MOH Russia

2. LLC «Center for Pharmacoeconomics Research»

Abstract

The article provides a brief overview of the main trends in the development of real-world data and real-world evidence (RWD/RWE) paradigm in the United States, Russia, and the Eurasian Economic Union (EAEU) in 2021. The review is compiled in calendar sequence. First, events in the United States are presented, sourced from the information resource, "The Evidence Base". Following this, data for the Russian Federation and the EAEU are collected and stored on the "myRWD — Real Clinical Practice" Facebook page, and in the journal "Real-World Data & Evidence". The information is summarized and a complete picture of the development of real clinical practice and its evidence in the indicated countries is given.

Publisher

Publishing House OKI

Reference24 articles.

1. Franklin JM, Patorno E, Desai RJ et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative. Circulation. 2020;143(10):1002–13.

2. Wang SV, Pinheiro S, Hua W et al. STaRT-RWE: structured template for planning and reporting on the implementation of real-world evidence studies. BMJ. 2021;372:m4856. doi: https://doi.org/10.1136/bmj.m4856

3. Pawlowski C, Lenehan P, Puranik A et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y). 2021;2(8):979–92.e8.

4. Pink Sheet. US FDA ‘Project Post COVIDity’ will track infection impact on cancer patients using real-world data. Режим доступа: www.pink.pharmaintelligence.informa.com/PS143790/USFDA-Project-Post-COVIDity-Will-Track-InfectionImpact-On-Cancer-Patients-Using-Real-World-Data (Accessed 16 December 2021).

5. Regan-Udall Foundation and Friends of Cancer Research. COVID-19 Evidence Accelerator. Режим доступа: www.evidenceaccelerator.org/ (Accessed 16 December 2021).

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3